32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1

Eisenhauer, E.; Therasse, Patrick; Bogaerts, J.; Schwartz, Larry; Sargent, Daniel J.; Ford, Robert; Dancey, Janet; Arbuck, Susan G.; Gwyther, Stephen J.; Mooney, Margaret; Rubenstein, Laurence H.; Shankar, Lalitha; Kaplan, Richard; Lacombe, Denis; Verweij, Jaap

doi:10.1016/s1359-6349(08)71964-5

Cited by 276 publications

(348 citation statements)

References 0 publications

Supporting

Mentioning

337

Contrasting

Unclassified

Order By: Relevance

“…PET scan response criteria were defined using the European Organization for Research and Treatment of Cancer (EORTC) criteria for PET response assessment and the International Working Group criteria for response assessment in lymphoma [18][19][20].…”

Section: Methodsmentioning

confidence: 99%

The role of ¹⁸F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia

et al. 2011

View full text Add to dashboard Cite

Disease assessment in WM is dependent on the quantification of the IgM monoclonal protein and percent involvement of the bone marrow. There is a need for imaging studies that objectively measure tumor load in these patients. In this study, we sought to examine the role of combined FDG-PET/CT imaging in the detection of tumor load and in the assessment of response to therapy. Thirty-five patients were enrolled on a prospective study using bortezomib and rituximab therapy and were included in this study because they completed a pre-and post-treatment FDG-PET/CT imaging at one facility (12 newly diagnosed and 23 relapsed/refractory). The use of combined FDG-PET/CT imaging showed positive findings in 83% of patients with WM, unlike prior studies using conventional imaging that indicate that only 20% of patients have lymphadenopathy or hepatosplenomegaly. Moreover, 43% of patients had abnormal bone marrow uptake on FDG-PET imaging that can potentially help in the assessment of their tumor load, especially with heterogenous sampling of the bone marrow. There was no statistical correlation between EORTC response criteria for FDG-PET/CT and response by monoclonal protein. This is the first study to examine the role of FDG-PET/CT imaging in WM. Future studies should examine the role of FDG-PET/CT in conjunction with monoclonal protein response in the assessment of progression-free survival in patients with WM. Am. J. Hematol. 86:567-572, 2011. V

show abstract

Section: Methodsmentioning

confidence: 99%

The role of ¹⁸F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia

et al. 2011

View full text Add to dashboard Cite

show abstract

“…rhIL-2 was administered in the following five days. The clinical responses were defined according to RECIST1.1 and immune-related response criteria (Eisenhauer et al, 2009;Wolchok et al, 2009). Adverse events were documented and graded based upon the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE 4.0).…”

Section: Conditioning Regimens and Infusion Of Car-t-egfr Cellsmentioning

confidence: 99%

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

Feng

Guo

Dai

et al. 2016

Sci. China Life Sci.

234

162

View full text Add to dashboard Cite

“…20,21 Complete response (CR) was defined as disappearance of all target lesions; partial response (PR) as at least a 30% decrease in the sum of diameters of target lesions; and progressive disease (PD) as at least a 20% increase in the sum of diameters of target lesions. Progressive disease was scored depending on whether it was intra-or extrahepatic.…”

Section: Study End Points and Follow-upmentioning

confidence: 99%